Monograph Details
|
|
Cardiovascular System
> CHF and arrhythmias
|
|
MAVIK |
| Manufacturer |
|
Abbott Laboratories |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
ACE inhibitor. |
| Generic Name |
|
Trandolapril 1mg+, 2mg, 4mg; tabs; +scored. |
| Indications |
|
In stabilized patients after MI, who have LV systolic dysfunction or CHF symptoms. |
| Children |
|
Not recommended. |
| Adults |
|
Initially 1mg once daily; titrate to 4mg once daily as tolerated. Renal dysfunction (CrCl <30mL/min) or hepatic cirrhosis: initially 0.5mg once daily. |
| Contraindications |
|
History of ACEI-associated or other angioedema. Pregnancy (Cat.D in 2nd and 3rd trimesters). |
| Precautions |
|
Renal impairment. Salt/volume depletion. Renal artery stenosis. Monitor for neutropenia in collagen vascular and/or renal disease. Monitor for hyperkalemia in diabetics. Dialysis (esp. high-flux membrane). Surgery. Discontinue if laryngeal edema, angioedema, or jaundice occurs. Avoid hypotension in CHF, aortic stenosis, ischemic heart disease, or cerebrovascular disease. Black patients may have higher risk of angioedema than non-black patients. Pregnancy (Cat.C in 1st trimester). Nursing mothers: not recommended. |
| Interactions |
|
Excessive hypotension with diuretics. Hyperkalemia with K+ supplements, K+-sparing diuretics, or salt substitutes. May increase lithium levels. |
| Adverse Reactions |
|
Cough, dizziness, hypotension, syncope, hyperkalemia, myalgia. |
| How Supplied |
|
Tabs—100 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
